| Project/Area Number |
08670736
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
FURUTAMA Daisuke (1997-1998) Faculty of Medicine, Osaka Medical College, Stuff, 医学部, 助手 (70291987)
木村 文治 (1996) 大阪医科大学, 医学部, 講師 (90204990)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TSUJI Kuniko Osaka Medical College, Reseach fellow, 医学部, 専攻医
TAGAMI Muneyoshi Osaka Medical College, Reseach fellow, 医学部, 専攻医
NAKAJIMA Hideto Osaka Medical College, Reseach fellow, 医学部, 専攻医
ITO Takumi Osaka Medical College, Reseach fellow, 医学部, 専攻医
SHINODA Keiichi Osaka Medical College, Assistant professor, 医学部, 講師 (60187367)
|
|---|
| Project Period (FY) |
1996 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1998: ¥400,000 (Direct Cost: ¥400,000)
Fiscal Year 1997: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1996: ¥900,000 (Direct Cost: ¥900,000)
|
|---|
| Keywords | amyotrophic lateral aclerosis / motoneuron / calcium channel / autoantibody / cell death / Amyotrophic latenal Sclersis / VSC 4.1 / polyglutamine / SBM4 |
|---|
| Research Abstract |
It was recently suggested that anti-voltage-gated calcium channel (VGCC) antibody in patients with amyotrophic lateral sclerosis (ALS) could enhance Ca2+ current and cause neuronal cell death. Although more than six distinct subtypes of al subunit of VGCC have been known, it has not been shown directly which neuronal type of al subunit is the target of antibodies in ALS, In this study, using type specific anti-al subunit antibodies, we tried to reveal al subtypes, to which antibodies in ALS serum bind. Anti-VGCC antibodies are positive in 25 to 65% of patients. The heterogeneity of anti-al subumt of VGCC antibodies in ALS serum was shown. Because type-specificity for antibodies vary among patients, contributions of these antibodies to ALS pathophysiology may differ with individual patients.
|
